Achilles Therapeutics to present a manufacturing update at the virtual 2020 AACR Annual Meeting

22/04/2020

Stevenage, UK 22 April, 2020 – Achilles Therapeutics (“Achilles”), a clinical-stage oncology company developing personalised cell therapies targeting clonal neoantigens, a novel class of tumour target, today announced that it will present a manufacturing update using the VELOSTM manufacturing platform for its lead programs at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting.

“This study using our VELOSTM manufacturing platform demonstrates the feasibility of generating clonal neoantigen T cells, or cNeT, for the treatment of NSCLC and recurrent or metastatic melanoma,” said Ed Samuel, SVP Manufacturing, Achilles Therapeutics. “Achilles is at a transformational stage in its development as we progress our two lead products into the clinic. We have prioritised our scaled GMP manufacturing platform from the inception of the Company in order to support our long-term strategy to develop a fully closed and automated manufacturing process which is central to our plans for scaling up production capabilities to deliver personalized cell therapies to patients.”

Oral Presentation details:

The virtual meeting is free and available to anyone by registering at aacr.org.

Presentation Title:

 

The development of a personalised autologous clonal neoantigen T cell therapy for the treatment of solid cancer using the VELOSTM manufacturing platform generates highly potent and reactive CD8+ and CD4+ T cells for clinical use
Presenter: Ed Samuel
Session Title: VCTPL05 – Adoptive Cell Transfer Therapy
Date and Presentation Time: April 28, 2020 – 11:55 – 12:05 PM EDT
Abstract Number: CT054

 

– Ends –

About Achilles Therapeutics

Achilles Therapeutics is a biopharmaceutical company developing personalised T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. Achilles uses DNA sequencing data from each patient, together with the proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop personalised T cell-based therapies specifically targeting those clonal neoantigens.
Achilles was founded in 2016 by lead investor Syncona Ltd and in September 2019 the Company raised £100M in an oversubscribed Series B financing led by RA Capital, cornerstoned by Syncona and joined by new investors including Forbion, Invus, Perceptive Advisors and Redmile Group. For further information please visit the Company’s website at: www.achillestx.com

Further information:

Achilles Therapeutics
Dr Iraj Ali – Chief Executive Officer
+44 (0)1438 906 906
media@achillestx.com

Julia Wilson – Head of Communications
+44 (0)7818 430877
j.wilson@achillestx.com

Consilium Strategic Communications
Mary-Jane Elliott, Sukaina Virji, Melissa Gardiner
Tel: +44 (0) 203 709 5000
Email: achillestx@consilium-comms.com

US Investor Relations – Solebury Trout
Lee Stern
+1 646-378-2922
lstern@troutgroup.com

AchillesLatest News

Achilles Therapeutics appoints Daniel Hood as Chief Legal Officer

07/07/2020

Stevenage, UK 7 July 2020 – Achilles Therapeutics (“Achilles”), a clinical stage biopharmaceutical company developing personalised cancer immunotherapies, today announces that...

Read More +

Achilles Therapeutics doses first patient in Phase I/II Study in advanced non-small cell lung cancer

23/06/2020

Stevenage, UK 23 June 2020 – Achilles Therapeutics (“Achilles”), a clinical stage biopharmaceutical company developing personalised cancer immunotherapies, today announced that...

Read More +

Achilles Therapeutics doses first patient in Phase I/II Study in recurrent or metastatic malignant melanoma with first TIL therapy to specifically target clonal neoantigens

29/05/2020

Stevenage, UK 29 May 2020 – Achilles Therapeutics (“Achilles”), a clinical stage biopharmaceutical company developing personalised cancer immunotherapies, today announced that...

Read More +